EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study

Jee Hoon Kim, See Young Lee, Galam Leem, Hee Seung Lee, Sung Ill Jang, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Si Young Song, Jae Hee Cho, Jung Hyun Jo

Translational Oncology · 2026-12 · 74 · 103085

DOI: 10.1016/j.tranon.2026.103085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Oncology, 2026-12. Verfasst von Jee Hoon Kim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; Institute of Gastroenterolo…. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Ministry of Trade Industry and Energy, Korea Ministry of Science and ICT, Korea Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

FOLFIRINOXGemcitabine/nab-paclitaxelNext-generation sequencingPancreatic cancerPropensity score matching

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, South Korea.
  • Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Division of Gastroenterology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
  • Division of Gastroenterology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: JHCHO9328@yuhs.ac.
  • Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, South Korea; Division of Gastroenterology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine,…

Förderung

  • Korea Ministry of Trade Industry and Energy
  • Korea Ministry of Science and ICT
  • Korea Ministry of Health and Welfare

Zitieren

APA

Kim, J. H., Lee, S. Y., Leem, G., Lee, H. S., Jang, S. I., Chung, M. J., Park, J. Y., Bang, S., Park, S. W., Song, S. Y., Cho, J. H., & Jo, J. H. (2026). FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study. Translational Oncology, 74, 103085. https://doi.org/10.1016/j.tranon.2026.103085

Vancouver

Kim JH, Lee SY, Leem G, Lee HS, Jang SI, Chung MJ, et al. FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study. Translational Oncology. 2026;74:103085. doi:10.1016/j.tranon.2026.103085

BibTeX
@article{Kim2026,
  author = {Kim, Jee Hoon and Lee, See Young and Leem, Galam and Lee, Hee Seung and Jang, Sung Ill and Chung, Moon Jae and Park, Jeong Youp and Bang, Seungmin and Park, Seung Woo and Song, Si Young and Cho, Jae Hee and Jo, Jung Hyun},
  title = {FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study},
  journal = {Translational Oncology},
  year = {2026},
  volume = {74},
  pages = {103085},
  doi = {10.1016/j.tranon.2026.103085}
}
Kostenlos starten →